HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Allows Supplement Firms More Time To Submit NDI Notifications, And For It To Respond

Executive Summary

More time for notifications than current deadline of at least 75 days before NDI-containing product is offered for sale in US doesn’t solve problems with FDA’s management of NDI regulation, say trade groups.

You may also be interested in...



The Dietary Supplement Market US FDA Is Regulating Isn’t Your 1994 DSHEA Version

“In the last 30 years, we've seen this sort of explosion, and it's not just more products and more sales. We're talking about more complex products,” says Cara Welch, FDA Office of Dietary Supplement Programs director. “Today's products are not the products from 1994.”

US Dietary Supplement Industry In 2023: Little New Expected In NDI Notification Enforcement

Chief executives of OTC drug and supplement industry trade groups discussed potential market and regulatory developments affecting their members’ businesses. HBW Insight concludes series here reporting on supplement sector’s outlook for FDA potentially resolving its protracted struggle with NDI notification requirement.

FDA Expects Closing Gap On NDI Notifications To Open Window Wider On Supplements Sold In US

FDA regulatory framework for VMS product manufacturing and marketing provides little pre-market transparency into what’s available in US, but it’s clear from post-market monitoring by the Office of Dietary Supplement Programs that compliance with the NDI notification requirement is lax.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS152538

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel